Markets:

Overview

News

Currencies

International

Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

60.82 +0.41 (+0.68%)

Streaming Delayed Price Updated: 12:24 PM EDT, Mar 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

CYTK Investor Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Cytokinetics, Inc.

September 19, 2025

From Robbins LLP

Via GlobeNewswire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Cytokinetics, Incorporated (CYTK) Investors To Inquire About Securities Fraud Class Action

September 19, 2025

From Glancy Prongay & Murray LLP

Via Business Wire

Levi & Korsinsky Reminds Cytokinetics, Incorporated Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 17, 2025 - CYTK

September 19, 2025

Via TheNewswire.com

Topics Earnings Fraud Lawsuit

Retail Buzz Soars As Cytokinetics Jumps 34% In Europe On Heart Drug Breakthrough ↗

September 01, 2025

Via Stocktwits

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 6, 2025 ↗

May 06, 2025

Via Benzinga

Levi & Korsinsky Reminds Cytokinetics, Incorporated Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 17, 2025 - CYTK

September 19, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Earnings Fraud Lawsuit

CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm

September 18, 2025

From The Schall Law Firm

Via Business Wire

CYTOKINETICS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cytokinetics, Incorporated and Encourages Investors to Contact the Firm

September 18, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Law Offices of Howard G. Smith Encourages Cytokinetics, Incorporated (CYTK) Investors to Inquire About Securities Fraud Class Action

September 18, 2025

From Law Offices of Howard G. Smith

Via Business Wire

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

September 18, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Here are the top movers in Tuesday's session. ↗

September 02, 2025

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Via Chartmill

10 Health Care Stocks Whale Activity In Today's Session ↗

September 02, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 02, 2025

Via Benzinga

Dow Tumbles Over 1%; Nio Shares Edge Lower After Q2 Results ↗

September 02, 2025

Via Benzinga

Topics Stocks

Top movers analysis in the middle of the day on 2025-09-02: top gainers and losers in today's session. ↗

September 02, 2025

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

Via Chartmill

Cytokinetics (CYTK) Stock Is Skyrocketing Tuesday: What's Driving The Action? ↗

September 02, 2025

Shares of Cytokinetics are trading sharply higher Tuesday. The company presented new long-term safety and efficacy data for its investigational drug, aficamten.

Via Benzinga

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

September 02, 2025

Via Benzinga

There are notable gap-ups and gap-downs in today's session. ↗

September 02, 2025

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

Tuesday's pre-market session: top gainers and losers ↗

September 02, 2025

As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 02, 2025

Via Benzinga

Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket ↗

September 02, 2025

Via Benzinga

Cytokinetics And The 'Provocative Conversation' That Could Rewrite Heart Disease ↗

August 30, 2025

Cytokinetics said Saturday its experimental treatment for a progressive heart disease outperformed standard beta blockers.

Via Investor's Business Daily

Tesla Stock 'Could Fall 90% Tomorrow,' Fund Manager Still Won't Buy — Here's Where He's Investing Instead ↗

August 26, 2025

A fund manager who beats 99% of his peers calls Tesla stock overvalued. Here's a look at some of his preferred investments.

Via Benzinga

CYTK Earnings Jump 3,065% ↗

August 07, 2025

Via The Motley Fool

Topics Economy Intellectual Property

Securities Fraud Investigation Into Cytokinetics, Incorporated (CYTK) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

May 08, 2025

From Glancy Prongay & Murray LLP

Via Business Wire

Cytokinetics, Incorporated (CYTK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

May 08, 2025

From Law Offices of Howard G. Smith

Via Business Wire

Securities Fraud Investigation Into Cytokinetics, Incorporated (CYTK) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

May 07, 2025

From Law Offices of Frank R. Cruz

Via Business Wire

CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm

May 02, 2025

From The Schall Law Firm

Via Business Wire

FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months ↗

May 02, 2025

FDA extended the aficamten decision deadline to Dec. 26 after classifying the REMS submission as a major amendment to the NDA review.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.